ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systems-based Studies"

  • Abstract Number: 0521 • ACR Convergence 2024

    Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in Rheumatoid Arthritis

    Ernest Choy1, Maria López Lasanta2, Paloma Vela-Casasempere3, Antonio Fernandez Nebro4, Santos Castañeda5, Carlos Marras6, Jaime Calvo-Alén7, Jesus Tornero8, Juan Cañete9, Eugeni Domènech10, Javier Gisbert11, José Manuel Carrascosa12, Eduardo Fonseca13, Luis Bujanda14, Valle García15, Britta Siegmund16, Giampiero Girolomoni17, Holger Heyn18, Pere Santamaria19, Richard M Myers20, yolanda Guillen21, Sergio H Martínez-Mateu22, Sara Marsal23 and Antonio Julia24, and IMID Consortium, 1Cardiff University School of Medicine, Cardiff, United Kingdom, 2Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, 3Hospital General Universitario Alicante, Alicante, Spain, 4Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, 5Hospital Universitario de la Princesa, Madrid, Spain, 6Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, 7Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, 8Hospital Universitario de Guadalajara, Guadalajara, Spain, 9Hospital Clinic an IDIBAPS, Barcelona, Spain, 10Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 11Hospital Universitario de la Princesa and IIS-IP, Madrid, Spain, 12Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 13Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 14Hospital Universitario de Donostia, San Sebastián, Spain, 15Hospital Universitario Reina Sofía, Córdoba, Spain, 16Charité – Universitätsmedizin Berlin, Berlin, Germany, 17University of Verona, Verona, Italy, 18Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, 19Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 20HudsonAlpha Institute for Biotechnology, Huntsville, AL, 21Imidomics, Inc, Barcelona, Spain, 22IMIDOMICs, Barcelona, Spain, 23Vall Hebron Hospital Research Institute, Barcelona, Spain, 24Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: Targeted therapies have failed to provide sustained disease remission in most patients suffering from immune-mediated inflammatory diseases (IMIDs). Combining existing drugs could overcome this…
  • Abstract Number: 0891 • ACR Convergence 2024

    Shared and Disease-Specific Mechanisms of Autoimmunity Using Single Cell Sequencing of Peripheral Immune Cells

    Jacquelyn Nestor1, Rachelly Normand1, Wamia Said1, Sergio Aguilar2, Nandini Samanta1, Sidney Martin1, Roya Best1, Hoang Anh Tran1, Adrien Antoinette1, Eilish Dillon3, Devin King3, April Jorge4, Maureen Leonard4, Pritha Sen3, Kerry Reynolds4, John Stone5, Michelle Rengarajan1, Tanuja Chitnis6, Kevin Wei7, Deepak Rao3, Andrew Luster8, Gary Reynolds1 and Alexandra-Chloe Villani1, 1Massachusetts General Hospital, Harvard Medical School, Broad Institute of MIT and Harvard, Boston, MA, 2National Center for Genomic Analysis, Barcelona, Spain, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Massachusetts General Hospital , Harvard Medical School, Concord, MA, 6Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 8Massachusetts General Hospital, Charlestown, MA

    Background/Purpose: Rheumatologic diseases are characterized by distinct clinical presentations and patterns of organ involvement, yet share many genetic risk factors and treatment responses. This suggests…
  • Abstract Number: 1431 • ACR Convergence 2024

    Computational Systems Biology Approach to Unveil Molecular Interactions in Sjogren’s Disease Pathogenesis

    Sacha E Silva Saffar1, Jacques-Eric Gottenberg2, Michele Bombardieri3, Divi Cornec4, Jacques-Olivier Pers4, Marta Alarcon-Riquelme5, Philippe Moigeon6, Michael Barnes7, Sandra Ng8, Wan Fai Ng9, Xavier Mariette10, Gaetane Nocturne10 and Anna Niaraki11, 1University Paris Saclay, Le Kremlin Bicetre, France, 2Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 3Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 4University of Brest, Brest, France, 5Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 6Servier Laboratories, France, Gif sur Yvette, France, 7William Harvey Research institute, Centre for Translational Bioinformatics, London, United Kingdom, 8Centre for Translational Bioinformatics, William Harvey Research Institute, London, United Kingdom, 9Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, 10Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 11University of Toulouse, Toulouse, France

    Background/Purpose: Sjögren's disease (SjD) presents an unmet medical challenge as there is currently no cure. Despite advances in understanding the immunopathogenesis of SjD, there is…
  • Abstract Number: 1094 • ACR Convergence 2023

    “Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis

    Christopher Macko1, Patty Chen2, Roger Santos3, Nirmala Ramalingam4, Nicole Tran5 and Sijie Zheng6, 1Kaiser Oakland Internal Medicine Residency, Piedmont, CA, 2Kaiser Oakland Medical Center Department of Rheumatology, Orinda, CA, 3Kaiser East Bay Department of Pharmacy, Oakland, CA, 4Kaiser Oakland Medical Center Department of Graduate Medical Education, Oakland, CA, 5Kaiser Oakland Department of Adult and Family Medicine, Oakland, CA, 6Kaiser Oakland Medical Center Department of Nephrology, Oakland, CA

    Background/Purpose: Lupus nephritis (LN) is the most common cause of kidney injury in patients with systemic lupus erythematous (SLE) and is associated with higher morbidity…
  • Abstract Number: 2124 • ACR Convergence 2023

    Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals

    Adam Savage1, Ziyuan He1, Marla Glass1, Julian Reading1, LauraKay Moss2, Marie Feser2, Vlad Tsaltskan3, Katherine Nguyen Nguyen3, Kristen Demoruelle2, kristine Kuhn4, David Boyle3, Cate Speake5, Xiao-Jun Li1, Peter Skene1, Troy Torgerson1, Tom Bumol1, V. Michael Holers6, Jane Buckner7, Gary Firestein8, kevin Deane2 and Mark Gillespie1, 1Allen Institute for Immunology, Seattle, WA, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of California San Diego, La Jolla, CA, 4University of Colorado School of Medicine, Aurora, CO, 5Benaroya Research Institute, Seattle, WA, 6University of Colorado, Denver, CO, 7Benaroya Research Institute at Virginia Mason, Seattle, WA, 8University of California San Diego, San Diego, CA

    Background/Purpose: Seropositive RA is preceded by an at-risk stage characterized by elevated circulating autoantibodies (AAb), including ACPA, in otherwise healthy individuals without clinically-apparent inflammatory arthritis.…
  • Abstract Number: 0077 • ACR Convergence 2022

    Rheumatoid Arthritis – Are We Getting to Target?

    myint Thway1, Gurjit S. Kaeley2, Karishma Ramsubeik3, Laurie Ramrattan1, Lilian Otalora Rojas4 and Sukhraj Singh1, 1University of Florida-Jacksonville, Jacksonville, FL, 2UF COM-J, Ponte Vedra Beach, FL, 3University of Florida, Jacksonville, FL, 4University of Florida, Ponte Vedra Beach, FL

    Background/Purpose: Low disease activity (LDA) is a key goal in treating Rheumatoid arthritis, but implementing the treat to target approach in clinical practice has been…
  • Abstract Number: 0329 • ACR Convergence 2022

    Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression

    Daniel Toro-Domínguez1, Manuel Martinez-Bueno1, Raúl López-Domínguez2, Jordi Martorell-Marugán1, Elena Carnero-Montoro1, Guillermo Barturen1, Daniel W. Goldman3, Michelle Petri3, Pedro Carmona-Sáez2 and Marta Alarcon-Riquelme1, 1Center for Genomics and Oncological Research (GENYO), Granada, Spain, 2University of Granada, Granada, Spain, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

    Background/Purpose: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to important worsening of quality of life and mortality. Flares appear unpredictably during the…
  • Abstract Number: 0640 • ACR Convergence 2022

    Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features

    Arnon Arazi1, Joseph Mears2, Thomas Eisenhaure3, Qian Xiao4, Paul Hoover4, Deepak Rao4, Celine Berthier5, Andrea Fava6, Siddarth Gurajala4, Michael Peters3, Tony Jones3, William Apruzzese4, Jennifer Barnas7, Richard Furie8, Anne Davidson9, David Hildeman10, Judith James11, Joel Guthridge11, Maria Dall'Era12, David Wofsy13, Peter Izmirly14, H Michael Belmont15, Robert Clancy14, Diane Kamen16, Chaim Putterman17, Thomas Tuschl18, Maureen McMahon19, Jennifer Grossman19, Kenneth Kalunian20, Michael Weisman21, Matthias Kretzler5, Michael Brenner22, Jennifer Anolik23, Michelle Petri24, Jill Buyon14, Soumya Raychaudhuri4, Nir Hacohen3, Betty Diamond9 and the Accelerating Medicines Partnership RA/SLE Network3, 1Feinstein Institutes for Medical Research, Melrose, MA, 2Michigan University, Ann Arbor, MI, 3Broad Institute, Cambridge, MA, 4Brigham and Women's Hospital, Boston, MA, 5University of Michigan, Ann Arbor, MI, 6Johns Hopkins University, Baltimore, MD, 7University of Rochester, Rochester, NY, 8Northwell Health, Great Neck, NY, 9Feinstein Institutes for Medical Research, Manhasset, NY, 10Cincinnati Children's Hospital, Cincinnati, OH, 11Oklahoma Medical Research Foundation, Oklahoma City, OK, 12University of California, Division of Rheumatology, San Francisco, CA, 13University of California San Francisco, SF, CA, 14NYU Grossman School of Medicine, New York, NY, 15NYU School of Medicine, New York, NY, 16Medical University of South Carolina, Charleston, SC, 17Albert Einstein College of Medicine, Bronx, NY, 18Rockefeller University, New York, NY, 19University of California Los Angeles, Los Angeles, CA, 20University of California San Diego, La Jolla, CA, 21Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, 22Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 23University of Rochester Medical Center, Rochester, NY, 24Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

    Background/Purpose: Lupus nephritis (LN) is characterized by considerable variability in its clinical manifestations and histopathological findings. Understanding the cellular and molecular mechanisms underlying this heterogeneity…
  • Abstract Number: 1139 • ACR Convergence 2022

    Molecular Pathways Identified from Risk Alleles Identify Mechanistic Differences in Systemic Lupus Erythematosus Patients of East Asian and European Ancestry

    Katherine Owen1, Kristy Bell2, Andrew Price3, Prathyusha Bachali4, Hannah Ainsworth5, Miranda Marion6, Timothy Howard5, Carl Langefeld7, Nan Shen8, Jinoos Yazdany9, Maria Dall'Era10, Amrie Grammer11 and Peter Lipsky3, 1RILITE, Crozet, VA, 2AMPEL BioSolutions LLC, Charlottesville, VA, 3AMPEL BioSolutions, Charlottesville, VA, 4AMPEL BioSolutions, Redmond, WA, 5Wake Forest School of Medicine, Winston-Salem, NC, 6Wake Forest University, Winston-Salem, NC, 7Wake Forest School of Medicine, Winston Salem, NC, 8Shanghai Jiang Tong University School of Medicine, Shanghai, China, 9UCSF, San Francisco, CA, 10University of California, Division of Rheumatology, San Francisco, CA, 11AMPEL LLC, Charlottesville, VA

    Background/Purpose: SLE is a multi-organ autoimmune disorder with a prominent genetic component. Individuals of Asian-Ancestry (AsA) disproportionately experience more severe SLE compared to individuals of…
  • Abstract Number: 0107 • ACR Convergence 2021

    Acceptability of the COVID-19 Vaccine in Patients with Rheumatic Diseases and Healthcare Professionals in 19 Arab Countries

    Lina El Kibbi1, Mona Metawee1, Ihsane Hmamouchi2, Nizar Abdulateef3, Hussein Halabi4, Mervat Eissa5, Manal El Rakawi6, Basel Masri7, Fatemah Abutiban8, Wafa Hamdi9, Asal Adnan3, Antonella Abi Najm10, Renaud Felten11, Laurent Arnaud11 and Nelly Ziade12, 1Specialized Medical Center, Riyadh, Saudi Arabia, 2Rheumatology Unit, Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, 3Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq, 4King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, 5Cairo University, Cairo, Egypt, Cairo, Egypt, 6Rheumatology Department, Douera Hospital, Faculty of Medicine, Saad Dahlab, Blida, Algeria, 7Jordan Hospital, Amman, Jordan, 8Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah Hospital, Kuwait City, Kuwait, 9Rheumatology Department, Kassab Institute of Orthopedics, UR17SP04, Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia, 10Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon, 11Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, 12Rheumatology Department, Saint-Joseph Medical University and Hotel-Dieu de France Hospital, Beirut, Lebanon

    Background/Purpose: The first COVID-19 vaccines were authorized in December 2020. However, their acceptability remains debated and has never been evaluated in patients with chronic rheumatic…
  • Abstract Number: 0523 • ACR Convergence 2021

    Transcriptional Subsetting of SLE Patient Cohorts Based on Metabolic Pathway Activity

    Diogo Camacho, Jennifer Swantek, Keng Soh, Jurre Kamphorst, Vivek Kaimal, John Monroe and Edward Driggers, Rheos Medicines, Inc, Cambridge, MA

    Background/Purpose: Systemic lupus erythematosus is a highly complex, heterogeneous, autoimmune disorder, with diverse clinical presentation and innate and adaptive immune system involvement. There is a…
  • Abstract Number: 1061 • ACR Convergence 2021

    Comparing Consultation Patterns Across Telehealth Platforms and Face-to-Face Clinic in the Military Health System

    Michael Loncharich, David DeSena, Angelique Collamer and Jess Edison, Walter Reed National Military Medical Center, Bethesda, MD

    Background/Purpose: Rheumatic diseases are often diagnostically challenging not only due to rarity, but also because symptoms can develop piecemeal before the diagnosis is clear. Access…
  • Abstract Number: 0596 • ACR Convergence 2020

    Clinical Academic Rheumatology: A Boon for Health Systems

    Kathleena D'Anna1, Karina Torralba2, Christina Downey3 and Carlos Silva Lynch4, 1Loma Linda University Medical Center, Moreno Valley, CA, 2Loma Linda University School of Medicine, Redlands, CA, 3Loma Linda University Medical Center, Redlands, CA, 4Loma Linda University Medical Center, Loma Linda

    Background/Purpose: Finding a balance between clinical and scholarly productivity is a challenge for many academic clinician-educator (CE) rheumatologists. An examination of workload and practice-generated downstream…
  • Abstract Number: 1481 • ACR Convergence 2020

    A Systematic Review to Quantify the Extent of Pharmaceutical Company Involvement in Rheumatology Consensus-Based Recommendations

    Dominique Feterman Jimenez1, Garret Duron2, Ali Duarte-Garcia3, Paul Sufka4, Samuel Whittle5, Philip Robinson6, Larry Prokop3 and Michael Putman7, 1UConn Health Center, Farmington, CT, 2HCA Memorial Health University Medical Center, Savannah, GA, 3Mayo Clinic, Rochester, MN, 4Healthpartners, St Paul, 5Rheumatology Unit, The Queen Elizabeth Hospital, Springfield, South Australia, Australia, 6University of Queensland, Herston, Queensland, Australia, 7Northwestern University, Chicago, IL

    Background/Purpose: Consensus-based recommendations guide standards of care for clinical practice. Pharmaceutical-industry involvement in producing such recommendations may undermine their objectivity. We performed a systematic review…
  • Abstract Number: 1564 • ACR Convergence 2020

    Feasibility of Ultra-low-dose, Short-duration, Total-body Evaluation of Inflammatory Arthritis Using uEXPLORER 18F-FDG PET/CT

    Soumajyoti Sarkar1, Siba Raychaudhuri2, Lorenzo Nardo3, Heather Hunt3, Denise Caudle4, Mike Nguyen4, Simon Cherry4, Ramsey Badawi4, Abhijit Chaudhari5 and Yasser Abdelhafez3, 1University of California, Davis, Davis, 2Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, 3University of California Davis, Sacramento, CA, 4University of California Davis, Sacramento, 5University of California, Davis, Sacramento, CA

    Background/Purpose: The uEXPLORER system enables the unique, simultaneous acquisition of PET data over the entire adult human body with a high-sensitivity, alongside concurrent CT data.…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology